Trillium Therapeutics (TRIL) Rating Lowered to Hold at Zacks Investment Research

Trillium Therapeutics (NASDAQ:TRIL) (TSE:TR) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a research note issued to investors on Friday. They presently have a $9.00 target price on the biotechnology company’s stock. Zacks Investment Research‘s price objective would suggest a potential upside of 16.88% from the stock’s previous close.

According to Zacks, “Trillium Therapeutics Inc. is a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s lead program, SIRPaFc (TTI-621), is a fusion protein that consists of the CD47-binding domain of human SIRPa linked to the Fc region of a human immunoglobulin (IgG1). It is designed to act as a soluble decoy receptor, preventing CD47 from delivering its inhibitory (do not eat) signal. Neutralization of the inhibitory CD47 signal enables the activation of macrophage anti-tumor effects by pro-phagocytic (eat) signals. A Phase 1 clinical trial (NCT02663518) evaluating SIRPaFc is ongoing. Trillium also has a proprietary medicinal chemistry platform, using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties. “

Several other equities research analysts have also issued reports on TRIL. ValuEngine upgraded Trillium Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, December 1st. HC Wainwright reiterated a “buy” rating and set a $10.00 price target on shares of Trillium Therapeutics in a report on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and an average price target of $12.33.

Shares of Trillium Therapeutics (NASDAQ TRIL) opened at $7.70 on Friday. The stock has a market capitalization of $88.91, a PE ratio of -2.03 and a beta of 1.78. The company has a debt-to-equity ratio of 0.01, a quick ratio of 6.33 and a current ratio of 6.33. Trillium Therapeutics has a 1-year low of $4.15 and a 1-year high of $13.30.

A number of institutional investors and hedge funds have recently bought and sold shares of TRIL. AWM Investment Company Inc. acquired a new stake in Trillium Therapeutics in the 2nd quarter worth approximately $4,415,000. Janus Henderson Group PLC acquired a new stake in Trillium Therapeutics in the 2nd quarter worth approximately $2,395,000. Tekla Capital Management LLC acquired a new stake in Trillium Therapeutics in the 2nd quarter worth approximately $1,980,000. Victory Capital Management Inc. lifted its holdings in Trillium Therapeutics by 88.9% in the 2nd quarter. Victory Capital Management Inc. now owns 146,571 shares of the biotechnology company’s stock worth $645,000 after purchasing an additional 68,970 shares during the last quarter. Finally, K2 Principal Fund L.P. acquired a new stake in Trillium Therapeutics in the 2nd quarter worth approximately $264,000. Hedge funds and other institutional investors own 47.18% of the company’s stock.

TRADEMARK VIOLATION WARNING: “Trillium Therapeutics (TRIL) Rating Lowered to Hold at Zacks Investment Research” was first published by Equities Focus and is the property of of Equities Focus. If you are accessing this article on another domain, it was illegally copied and republished in violation of United States & international copyright and trademark legislation. The correct version of this article can be read at https://www.equitiesfocus.com/2018/01/07/trillium-therapeutics-tril-rating-lowered-to-hold-at-zacks-investment-research.html.

About Trillium Therapeutics

Trillium Therapeutics Inc, a clinical-stage immuno-oncology company, develops therapies for the treatment of cancer. The company’s lead program is TTI-621, a SIRPaFc fusion protein that acts a soluble decoy receptor preventing CD47 from delivering its inhibitory signal, which is in Phase I clinical trial for advanced hematologic malignancies and solid tumors therapy.

Get a free copy of the Zacks research report on Trillium Therapeutics (TRIL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Trillium Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trillium Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply